CSS
MRTX

Cubist Systematic Strategies’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Cubist Systematic Strategies’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,869
Closed -$874K – 4444
2023
Q4 		$874K Sell
14,869
-6,036
-29% -$339K 0.01% 2147
2023
Q3 		$911K Buy
+20,905
New +$746K 0.01% 1944
2023
Q2 		– Sell
-67,132
Closed -$2.5M – 4519
2023
Q1 		$2.5M Buy
67,132
+56,929
+558% +$2.56M 0.02% 1493
2022
Q4 		$462K Buy
10,203
+2,479
+32% +$160K ﹤0.01% 3078
2022
Q3 		$539K Sell
7,724
-14,536
-65% -$1.08M ﹤0.01% 3107
2022
Q2 		$1.49M Sell
22,260
-3,533
-14% -$225K 0.01% 2129
2022
Q1 		$2.12M Buy
25,793
+18,050
+233% +$1.85M 0.02% 1418
2021
Q4 		$1.14M Sell
7,743
-6,773
-47% -$1.05M 0.01% 1825
2021
Q3 		$2.57M Sell
14,516
-38,370
-73% -$6.17M 0.03% 850
2021
Q2 		$8.54M Buy
52,886
+39,715
+302% +$6.38M 0.1% 277
2021
Q1 		$2.26M Buy
13,171
+3,146
+31% +$623K 0.03% 946
2020
Q4 		$2.2M Buy
10,025
+3,123
+45% +$675K 0.03% 885
2020
Q3 		$1.15M Buy
6,902
+3,493
+102% +$478K 0.02% 1247
2020
Q2 		$389K Buy
+3,409
New +$331K 0.01% 1715
2020
Q1 		– Sell
-11,100
Closed -$1.43M – 2541
2019
Q4 		$1.43M Buy
11,100
+10,814
+3,781% +$1.04M 0.03% 940
2019
Q3 		$22K Sell
286
-20,781
-99% -$1.95M ﹤0.01% 2115
2019
Q2 		$2.17M Buy
+21,067
New +$1.64M 0.04% 643
2018
Q4 		– Sell
-100
Closed -$5K – 2330
2018
Q3 		$5K Buy
+100
New +$5.57K ﹤0.01% 1839
2018
Q2 		– Sell
-6,302
Closed -$193K – 2114
2018
Q1 		$193K Buy
+6,302
New +$175K 0.01% 1418
2016
Q1 		– Sell
-6,667
Closed -$211K – 1888
2015
Q4 		$211K Buy
6,667
+5,836
+702% +$206K 0.01% 1324
2015
Q3 		$29K Buy
+831
New +$25.1K ﹤0.01% 1761

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cubist Systematic Strategies's MRTX Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 14,869 shares — an estimated $874K sold.

Cubist Systematic Strategies first reported a position in MRTX in Q3 2015 and held it in 21 quarters. The position peaked at $8.54M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 14,869 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $874K.
  • Cubist Systematic Strategies first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 21 quarters.
  • Cubist Systematic Strategies's Mirati Therapeutics, Inc. Common Stock position peaked at $8.54M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.